Glucagon-like peptide-1 agonist
Glucagon-like peptide-1 receptor agonists also known as GLP-1 receptor agonists or incretin mimetics are agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages over older insulin secretagogues, such as sulfonylureas or meglitinides, is that they have a lower risk of causing hypoglycemia.
There is some concern over the safety profile of these drugs due to proliferative effects in the pancreas.
Approved GLP-1 agonists:
- exenatide (Byetta/Bydureon), approved in 2005/2012
- liraglutide (Victoza, Saxenda), approved 2010
- lixisenatide (Lyxumia), approved in EU 2013
- albiglutide (Tanzeum), approved in 2014 by GSK
- dulaglutide (Trulicity), approved in 2014 - manufactured by Eli Lily K
Under investigation: 
- taspoglutide, phase III halted Sept 2010,
- Baggio LL (2008). "Glucagon-like Peptide-1 Analogs Other Than Exenatide". Medscape Diabetes & Endocrinology.
- "Standards of medical care in diabetes--2012". Diabetes Care. 35 Suppl 1: S11–63. 2012. doi:10.2337/dc12-s011. PMC 3632172. PMID 22187469.
- Schweizer M, Perencevich E, McDanel J, Carson J, Formanek M, Hafner J, Braun B, Herwaldt L (2013). "Effectiveness of a bundled intervention of decolonization and prophylaxis to decrease Gram positive surgical site infections after cardiac or orthopedic surgery: systematic review and meta-analysis". BMJ 346: f2743. doi:10.1136/bmj.f2743. PMC 3681273. PMID 23766464.
- "FDA Approves New Treatment for Type 2 Diabetes".
- "Sanofi New Drug Application for Lixisenatide Accepted for Review by FDA".
- "FDA Approves Weekly Injectable Diabetes Drug: Albiglutide".
- "FDA Approves Weekly Injectable Diabetes Drug: Dulaglutide".
- "GLP-1 Receptor Agonists vs. DPP-4 Inhibitors for Type 2 Diabetes".
|This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.|